Shiraz University of Medical Sciences
Middle East Journal of Cancer
2008-6709
8
1
2017
01
01
Treatment of Hormone Resistance with Docetaxel in Metastatic Prostate Cancer Patients: Results of a Clinical Experience at Omid Hospital, Isfahan, Iran
1
6
42060
EN
Mina
Tajvidi
Department of Radiation Oncology, School of Medicine, Isfahan University of Medical
Sciences, Isfahan, Iran
Mahnaz
Roayaei
Department of Radiation Oncology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
Simin
Hematti
Department of Radiation Oncology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
Hadi
Faezi
Department of Radiation Oncology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
0000-0002-6303-3454
Journal Article
2016
12
26
Background: Metastatic prostate cancer is one of the most important cancers among men worldwide. Androgen ablation therapy can be used in treatment of these patients; however, most will progress to metastatic hormone-refractory prostate cancer. In this regard, docetaxel has been approved to treat metastatic hormone-refractory prostate cancer in the United States. In this study, we aimed to investigate the results of this treatment modality in metastatic prostate cancer patients from Iran.Methods:We evaluated PSA response and bone pain relief in 18 metastatic prostate cancer patients who underwent treatment with docetaxel at a dose of 75 mg/m2 intravenously on the first day of treatment. The treatment was repeated every three weeks (6 cycles) along with 10 mg of prednisolone.Results: Of 18 patients, 39% had >50% decline in PSA levels.There were 16% of the patients with a PSA decline of approximately 30% to 50% of the pre-treatment levels. In addition, 29% of the patients had progressive PSA levels during chemotherapy. Among them, 55% had significant pain relief.Conclusion: This research showed the effectiveness of docetaxel to decrease PSA levels in metastatic hormone-refractory prostate cancer patients from Iran. Docetaxel was also valuable in alleviation of pain in these patients. However, prospective studies should validate this approach.
https://mejc.sums.ac.ir/article_42060_24c0188c132ee9a41c2a50d2432fe656.pdf
Shiraz University of Medical Sciences
Middle East Journal of Cancer
2008-6709
8
1
2017
01
01
Association of Glutathione S-transferase Genes (M1 and T1) with the Risk of Acute Myeloid Leukemia in a Moroccan Population
7
12
42063
EN
Ait Boujmia
Oum Kaltoum
Laboratory of Genetics and Molecular Pathology, Medical School, University Hassan II, Casablanca, Morocco
0000-0002-1014-9728
Nadifi
Sellama
Laboratory of Genetics and Molecular Pathology, Medical School, University Hassan II, Casablanca, Morocco
Dehbi
Hind
Laboratory of Genetics and Molecular Pathology, Medical School, University Hassan II, Casablanca, Morocco
Kassogue
Yaya
Laboratory of Genetics and Molecular Pathology, Medical School, University Hassan II, Casablanca, Morocco
Lamchahab
Mouna
Department of Onco-Hematology, Ibn Rochd University Hospital, Casablanca, Morocco
Quessar
Asma
Department of Onco-Hematology, Ibn Rochd University Hospital, Casablanca, Morocco
Journal Article
2016
06
24
Background: Acute myeloid leukemia, as most cancers, results from exposure to carcinogens and an impaired inherited individual capacity to eliminate xenobiotics. The present case-control study measures the relationship between glutathione S-transferase (GST) T1 and M1 null genotypes and the risk of acute myeloid leukemia.Methods: We identified the GSTT1 andGSTM1 genotypes by multiplex polymerase chain reaction in 129 acute myeloid leukemia patients and 129 controls.Results: Individuals that carried GSTT1 null had a risk of acute myeloid leukemia when compared to GSTT1 present carriers (OR: 2.80; 95% CI: 1.63-4.80, P=0.00036). However, GSTM1 null did not influence the risk for acute myeloid leukemia (OR: 1.20; 95% CI: 0.72-1.97, P=0.53). The combined GSTT1 null/GSTM1 present genotype showed an association with the risk for acute myeloid leukemia compared to those that carried both functional genotypes (OR: 8.85; 95% CI: 3.09-23.8, P=0.0001). The double null genotype also showed an association with the risk for acute myeloid leukemia (OR: 2.32, 95% CI: 1.15-4.66, P=0.019).Conclusion: Both GSTT1 null and GST double-null genotypes may be risk factors for acute myeloid leukemia. Further studies are needed to confirm these results.
https://mejc.sums.ac.ir/article_42063_f2115e17e8914659a2d817201dfa80ee.pdf
Shiraz University of Medical Sciences
Middle East Journal of Cancer
2008-6709
8
1
2017
01
01
Interplay between CKS2, N-cadherin, and PD-ECGF in Non-Schistosomal and Schistosomal-Associated Bladder Cancer: A Prospective Comparative Study in the Egyptian Population
13
30
42064
EN
Sanaa
Shawky
Pathology Department, Medical Research Institute (MRI), Alexandria University, Egypt
Mona
Salem
Pathology Department, Faculty of Medicine, Alexandria University, Egypt
Hoda
Abou Seif
Pathology Department, Medical Research Institute (MRI), Alexandria University, Egypt
Salah El Din
El Salmy
Urology Department, Faculty of Medicine, Alexandria University, Egypt
Manal
Sheta
Pathology Department, Medical Research Institute (MRI), Alexandria University, Egypt
Eman
El-Abd
Radiation Sciences Department, MRI, Alexandria University, Egypt
Molecular Biology Department, Medical Technology Centre (MTC), MRI, Alexandria University, Egypt
Journal Article
2016
10
02
Background: The current study investigated the possible role of the cell cycle regulator, cyclin-dependent kinases regulatory subunit-2; the angiogenic factor, plateletderived endothelial cell growth factor; and the cell adhesive molecule, neural cadherin, as prognostic factors in schistosomal and non-schistosomal-associated urothelial carcinomas. We also investigated the possible correlation between cyclin-dependent kinases regulatory subunit-2, platelet-derived endothelial cell growth factor, neural cadherin, tumor grade, and stage.Methods: The study included 40 patients with primary bladder cancer (25 nonschistosomal- associated and 15 schistosomal-associated) who had no prior anticancer treatment. Tumor specimens were collected at the time of the transurethral resection. The vivid portions of the resected tumors were subjected to routine pathological examinations to determine stage, grade, and schistosomal infestation. Control bladder tissues (5 cases) were obtained by cystoscopic biopsies from patients who underwent transurethral resection of the prostate. Platelet-derived endothelial cell growth factor and neural cadherin protein expressions were evaluated by immunohistochemical staining. RNA was extracted, reverse transcribed, and amplified by PCR using cyclindependent kinases regulatory subunit-2 specific primers. Relative expression was detected by a comparison of the expression in normal and tumor samples relative to GAPDH (housekeeping) gene expression.Results:We detected a positive correlation between neural cadherin and plateletderived endothelial cell growth factor proteins in schistosomal-associated and non-schistosomal-associated bladder cancer. Significant overexpression of relative cyclin-dependent kinases regulatory subunit-2 gene, neural cadherin, and plateletderived endothelial cell growth factor proteins were detected in invasive stages and higher grades of bladder cancer. Differential expressions of neural cadherin and plateletderived endothelial cell growth factor proteins, tumor recurrence, and tumor progression were detected between schistosomal-associated and non-schistosomal-associated bladder cancer.Conclusion: Cyclin-dependent kinases regulatory subunit-2, neural cadherin, and platelet-derived endothelial cell growth factor may be used as biomarkers for predicting bladder cancer outcome and aid in selecting patients for more aggressive treatments.
https://mejc.sums.ac.ir/article_42064_96b067a6aa6eeea2d8b5fa66e21d9068.pdf
Shiraz University of Medical Sciences
Middle East Journal of Cancer
2008-6709
8
1
2017
01
01
The Synergistic Effects of the Combination of Ciprofloxacin and Temozolomide on Human Glioblastoma A-172 Cell Line
31
38
42066
EN
Ashkan
Zandi
Department of Pharmacology, School of Medicine, Shahid Beheshti University of Medical
Sciences, Tehran, Iran
Taraneh
Moini Zanjani
Department of Pharmacology, School of Medicine, Shahid Beheshti University of Medical
Sciences, Tehran, Iran
Seyed Ali
Ziai
Department of Pharmacology, School of Medicine, Shahid Beheshti University of Medical
Sciences, Tehran, Iran
Yalda
Khazaei Poul
Department of Pharmacology, School of Medicine, Shahid Beheshti University of Medical
Sciences, Tehran, Iran
Mostafa
Haji Molla Hoseini
Department of Immunology, School of Medicine, Shahid Beheshti University of Medical
Sciences, Tehran, Iran
Journal Article
2016
07
05
Background: Combination therapy has generated remarkable motivation in the clinical setting since it boosts the therapeutic potential of anticancer drugs. Glioblastoma multiforme (GBM) is the most common and aggressive malignant brain tumor which affects patients in all ages, and being principally resistant to treatment. Methods: In this study, temozolomide as a standard chemotherapeutic drug for Human GBM, was combined with ciprofloxacin to know whether ciprofloxacin can potentiate the cytotoxic effects of temozolomide. Glioblastoma A-172 cell line was exposed to ciprofloxacin and temozolomide either alone or in combination for 24, 48 and 72 h. Cytotoxicity was measured by MTT assay. Results: Ciprofloxacin and temozolomide induced tumor cell death in a dose-dependent manner with an IC50 value of 259.3 μM for ciprofloxacin and 62.5 μM for temozolomide in 72 h. These values shifted to 22.8 μM for ciprofloxacin and 8.6 μM for temozolomide in the presence of IC50 of the other drug. The combination-index (CI) values were found less than 1. Conclusion: These results indicate synergism across a broad range of concentrations of ciprofloxacin and temozolomide in glioblastoma tumor cell line and that CPF increased the anti-tumor cytotoxic effect of TMZ in glioblastoma A-172 cell line.
https://mejc.sums.ac.ir/article_42066_094c200b752b656c01073b609bb8019e.pdf
Shiraz University of Medical Sciences
Middle East Journal of Cancer
2008-6709
8
1
2017
01
01
Incidence Rate and Distribution of Common Cancers among Iranian Children
39
42
42061
EN
Salman
Khazaei
Department of Epidemiology, School of Public Health, Hamadan University of Medical Sciences, Hamadan, Iran
Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
Erfan
Ayubi
Department of Epidemiology, School of Public Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran
0000-0002-8829-9304
Mokhtar
Soheylizad
Social Determinants in Health Promotion Research Center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran
Kamyar
Manosri
Social Development and Health Promotion Research Center, Gonabad University of Medical Sciences, Gonabad, Iran
Department of Epidemiology, School of Public Health, Iran University of Medical Sciences, Tehran, Iran
0000-0003-3527-4741
Journal Article
2016
06
25
Background: Geographic differences in the incidence of cancers may suggest unique genetic or environmental exposures that impact the risk of acquiring cancer. This research aims to determine the incidence rate and geographical distribution of common cancers among Iranian children.Methods: In this ecological study, we extracted data that pertained to the incidence rate of common cancers among children from reports by the National Registry of Cancer and Disease Control and Prevention in 2008. A map of the cancer incidence rates was designed by using geographic information system.Results:The most common cancer sites among children were the hematology system, brain and central nervous system, and lymph nodes. The central provinces had the lowest cancer incidences.Conclusion: The considerable variation in incidence of childhood cancers in Iran suggests a possible potential environmental risk factor or genetic background related to this increased risk among children.
https://mejc.sums.ac.ir/article_42061_02cc2b043bafbe6306ba6eac15d8ca7c.pdf
Shiraz University of Medical Sciences
Middle East Journal of Cancer
2008-6709
8
1
2017
01
01
Primary Diffuse Large Cell Lymphoma of the Bladder: Case Report and Literature Review
43
48
42059
EN
Mansour
Ansari
Breast Diseases Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
0000-0002-8249-1776
Hamid
Nasrollahi
Department of Radiation Oncology, Shiraz University of Medical Sciences, Shiraz, Iran
0000-0002-7423-3312
Majdaddin
Rajaei
Department of Radiation Oncology, Shiraz University of Medical Sciences, Shiraz, Iran
Maral
Mokhtari
Department of Pathology, Shiraz University of Medical Sciences, Shiraz, Iran
0000-0002-4815-2631
Seyed Hasan
Hamedi
Department of Radiation Oncology, Shiraz University of Medical Sciences, Shiraz, Iran
0000-0002-2050-5909
Mohammad
Mohammadianpanah
Colorectal Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
0000-0001-9391-8977
Shapour
Omidvari
Breast Diseases Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
0000-0003-3656-9891
Ahmad
Mosalaei
Shiraz Institute for Cancer Research, Shiraz University of Medical Sciences,
Shiraz, Iran
0000-0002-3986-8865
Niloofar
Ahmadloo
Colorectal Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
0000-0003-3178-8577
Journal Article
2016
05
08
Most bladder tumors are epithelial in origin. Nonepithelial cancers are rarely located in the bladder. Sarcomas are the most common malignancies among nonepithelial cancers. Primary bladder lymphoma is rare and mostly low grade. Here, we have reported a case of diffuse large cell lymphoma of the bladder. The patient, a 64-year-old man, had urinary frequency for 18 months. Abdominal sonography indicated a thick bladder wall and transurethral biopsy showed diffuse large cell lymphoma. Immunohistochemistry (IHC) results showed that the tumor was positive for CD20, CD45, and Pax-5 and negative for BCL-2, cytokeratin, and S100. He had a normal bone marrow biopsy, abdominal, pelvic and chest CT scans. He had no B symptoms. The patient received 6 cycles of R-CHOP followed by radiotherapy (36 Gy) to the pelvis. Six months after treatment, the patient is well and has returned to work. We have searched PubMed for primary diffuse large cell lymphoma. Primary diffuse large cell lymphoma of the bladder is best treated according to treatment for diffuse large cell lymphoma of other sites, which includes chemotherapy and radiotherapy. As seen in our review, primary diffuse large cell lymphoma of the bladder has a similar clinical course to diffuse large cell lymphoma of other sites.
https://mejc.sums.ac.ir/article_42059_a4f313847bb4396ecf2f36de9148362f.pdf
Shiraz University of Medical Sciences
Middle East Journal of Cancer
2008-6709
8
1
2017
01
01
Struma Ovarii Associated with Pseudo-Meigs’ Syndrome: A Rare Presentation of an Infrequent Tumor
49
55
42062
EN
Sonia
Chhabra
Department of Pathology, Post Graduate Institute of Medical Sciences (PGIMS),
Rohtak, Haryana, India
Namita
Bhutani
Department of Pathology, Post Graduate Institute of Medical Sciences (PGIMS),
Rohtak, Haryana, India
0000-0003-2436-9016
Sunita
Singh
Department of Pathology, Post Graduate Institute of Medical Sciences (PGIMS),
Rohtak, Haryana, India
Mansi
Aggarwal
Department of Pathology, Post Graduate Institute of Medical Sciences (PGIMS),
Rohtak, Haryana, India
Rajeev
Sen
Department of Pathology, Post Graduate Institute of Medical Sciences (PGIMS),
Rohtak, Haryana, India
0000-0001-7957-5613
Journal Article
2016
10
04
Struma ovarii is an uncommon highly specialized ovarian teratoma that accounts for less than 5% of mature teratomas. It is composed predominantly of mature thyroid tissue. Thyroid tissue is observed in 5%-15% of teratomas; however, to qualify as a struma ovarii tumor, the thyroid proportion must comprise more than 50% of the overall tissue. The combination of pseudo Meigs'syndrome and elevation of CA 125 with struma ovarii is a rare condition that can mimic ovarian malignancy. The majority of strumas are benign, however occasionally malignant transformation may be seen. We have reported a case of benign struma ovarii that presented with the clinical features of advanced ovarian carcinoma: complex pelvic mass, gross ascites, bilateral pleural effusion, and markedly elevated serum CA 125 levels. The patient underwent total abdominal hysterectomy and bilateral salpingo oophorectomy. Ascites and pleural effusion resolved completely, and the CA 125 levels have returned to normal following surgical excision. Patients with pseudo-Meigs’ syndrome may present a diagnostic problem as they masquerade as carcinoma with malignant effusions. In addition, the coexistence of struma ovarii and pseudo-Meigs’ syndrome is a very rare event. We emphasize by this report that, despite its rarity, a differential diagnosis of struma ovarii should be included for an ovarian mass.
https://mejc.sums.ac.ir/article_42062_171bf5808bd51ee2ad3a2485c3c487f3.pdf
Shiraz University of Medical Sciences
Middle East Journal of Cancer
2008-6709
8
1
2017
01
01
Myxofibrosarcoma of the Breast in a Young Pregnant Woman: A Case Report and Review of the Literature
57
62
42065
EN
Fatemeh
Nili
Department of Pathology, Cancer Institute, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran
Elham
Asadinejad
Department of Pathology, Cancer Institute, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran
Hana
Saffar
Department of Pathology, Cancer Institute, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran
Alireza
Ghanadan
Department of Pathology, Cancer Institute, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran
Department of Dermatopathology, Razi Dermatology Hospital, Tehran University of Medical Sciences, Tehran, Iran
Journal Article
2016
05
15
Sarcomas of the breast are rare and comprise less than 1% of mammary cancers. Myxofibrosarcoma as an unusual variant of malignant fibrous histiocytoma in the breast and during pregnancy has not previous been reported in the literature. We present the case of a 32-year-old woman with a rapidly growing subcutaneous left breast mass that appeared during her first pregnancy. After ultrasonography and core needle biopsy, she underwent a modified radical mastectomy. Pathologic examination revealed a multinodular subcutaneous mass with characteristic microscopic features consistent with myxofibrosarcoma. Immunohistochemistry findings supported the diagnosis and excluded other differential diagnoses. There has been no consensus about proper management and surveillance in these rare groups of malignancies, however wide local excision and adjuvant treatment for moderate and high grade tumors are recommended.
https://mejc.sums.ac.ir/article_42065_2e4b7e1951ee1e691c741ddeef167c3a.pdf
Shiraz University of Medical Sciences
Middle East Journal of Cancer
2008-6709
8
1
2017
01
01
Calendar of Events
63
42058
EN
Journal Article
2017
03
08
https://mejc.sums.ac.ir/article_42058_b6d15f0d65648d7b1b8e8640566ccf3c.pdf